In its latest SEC filing, Generali Asset Management SPA SGR disclosed a 51.6% increase in its holdings of Illumina shares during the third quarter. The firm purchased an additional 7,574 shares, bringing its total position to 22,249 shares valued at $2.113 million. This marks one of the largest single-quarter increases for Illumina by a European asset manager in 2024, reflecting confidence in the company’s long-term sequencing and array technologies.

Several leading hedge funds and asset managers rebalanced their Illumina exposure in the second quarter. WCM Investment Management added 247,460 shares, lifting its stake to approximately 4.43 million shares—an increase of 5.9% and now the largest single institutional position, valued at over $419 million. AQR Capital Management executed the most aggressive move, boosting its shares by 55.3% (1.17 million additional shares) to hold roughly 3.30 million shares worth $313 million. Loomis Sayles, Geode Capital Management and UBS AM also expanded their stakes by 1.9%, 0.7% and 51.7%, respectively, underlining broad institutional support ahead of year-end portfolio reviews.

Illumina reported Q3 earnings per share of $1.34, surpassing consensus estimates by $0.18, on revenue of $1.08 billion—slightly above analyst projections of $1.07 billion and representing a 0.4% year-over-year increase. Return on equity stood at 29.2% with a net margin of 16.4%. Management set full-year 2025 EPS guidance between $4.65 and $4.75, up from prior guidance of $4.50–$4.60, signaling confidence in continued demand for next-generation sequencing consumables and instrument upgrades. Analysts’ average estimate for FY25 stands at $4.51 per share.